Long-term outcomes and prognostic factors of patients with obstructive colorectal cancer: A multicenter retrospective cohort study

Table 1 Clinicopathological characteristic of patients with obstructive colorectal cancer n (%)

Variable	Category	n = 234
Gender	Male	141(60.3)
	Female	93 (39.7)
Age (yr)1		71 (35-96)
ASA	I	70 (30)
	II	128 (54.7)
	III	36 (15.3)
Location of tumor	Cecum	10 (4.3)
	Ascending colon	33 (14.1)
	Transverse colon	33 (14.1)
	Descending colon	36 (15.4)
	Sigmoid colon	95 (40.6)
	Rectum	15 (10.5)
Decompression	+	183 (78.2)
	-	51 (21.8)
CEA (mg/dL) 1		4.9 (0.3-2470)
Serum albumin1		3.4 (1.4-4.9)
Tumor size(mm)		48 (10-140）
Depth of tumor	pT3	109 (46.6)
	pT4a	93 (39.7)
	pT4b	32 (13.7)
Lymph node involvement	N0	113 (48.3)
	N1	90 (38.5)
	N2	31 (13.2)
R0 resection	+	219 (93.6)
	-	15 (6.4)
Adjuvant chemotherapy	+	91 (38.9)
	-	143 (61.1)

¹Median (range).

Table 2 Patterns of recurrence following colorectal resection of obstructive colorectal cancer (n = 71)

Site of recurrence	n (%)
Liver	27 (11.5)
Lung	22 (9.4)
Peritoneal dissemination	21 (9.0)
Local recurrence	9 (3.8)
Lymph node	6 (2.6)
Anastomosis	3 (1.3)
Abdominal wall	2 (0.9)
Pleural dissemination	2 (0.9)

Table 3 Result of the univariate and multivariate analysis of risk factors for recurrence

Factor		n	Univariate analysis			Multivariate analysis
			3-yr RFS	5-yr RFS	P value	HR (95%CI)	P value
Gender	M	141	59.2%	47.6%	0.409
	F	93	66.8%	54.7%
Age (yr)	≥ 75	96	55.0%	42.4%	0.011	1.228 (0.659-2.290)	0.518
	< 75	138	67.3%	55.9%
ASA-PS	1	71	75.7%	64.8%	0.017	2.234 (1.101-4.535)	0.026
	2-3	163	56.6%	44.6%
BMI (kg/m2)	≥ 25	28	66.0%	49.7%	0.951
	< 25	193	62.7%	52.7%
Serum albumin (g/dL)	≤ 4.0	172	54.9%	41.3%	0.001	2.967 (1.342-6.560)	0.007
	> 4.0	48	79.7%	73.1%
CEA (mg/dL)	≥ 5.0	102	52.4%	44.8%	0.052
	< 5.0	113	74.1%	54.2%
Decompression	+	183	62.9%	50.7%	0.572
	-	51	60.5%	50.4%
Location of tumor	Right side	69	62.5%	55.5%	0.738
	Left side	165	62.1%	48.7%
Tumor size (mm)	≥ 50	99	61.0%	48.8%	0.384
	< 50	121	63.9%	54.1%
Differentiation of tumor	tub1,tub2	222	63.7%	51.2%	0.080
	por, muc	12	36.7%	36.7%
Depth of tumor	T3	108	73.5%	64.7%	0.001	2.728 (1.467-5.072)	0.002
	T4	126	53.0%	38.7%
Intramural lymphatic invasion	+	157	61.4%	53.2%	0.600
	-	73	64.4%	45.2%
Intramural vascular invasion	+	164	60.3%	49.3%	0.683
	-	70	68.1%	57.4%
Lymph node involvement	+	120	65.7%	47.4%	0.856
	-	114	59.1%	53.2%
Lymph node dissection	D0,D1	31	44.3%	44.3%	0.067
	D2,D3	199	64.7%	50.8%
No. of lymph nodes harvested	< 12	73	54.8%	44.5%	0.085
	≥ 12	151	66.4%	52.5%
Postoperative complication	+	78	57.3%	44.7%	0.071
(≥ Grade 2)	-	156	64.7%	53.5%
Anastomotic leakage	+	18	71.1%	56.9%	0.562
	-	191	61.7%	50.0%
Curability	R0	219	66.4%	54.8%	< 0.001	6.555 (1.344-31.970)	0.020
	R1	15	7.6%	0.0%
Adjuvant chemotherapy	+	91	66.2%	55.6%	0.069
	-	143	59.8%	47.2%

Table 4 Result of the univariate and multivariate analysis of prognostic factors for cancer-specific survival

Factor		n	Univariate analysis			Multivariate analysis
			3-yr CSS	5-yr CSS	P value	HR(95%CI)	P value
Gender	M	141	88.3%	80.8%	0.924
	F	93	87.8%	79.7%
Age (yr)	≥ 75	96	82.2%	71.6%	0.027	1.464 (0.647-3.310)	0.360
	< 75	138	91.9%	85.4%
ASA-PS	1	71	86.0%	83.5%	0.710
	2-3	163	89.0%	78.7%
BMI (kg/m2)	≥ 25	28	92.0%	85.8%	0.389
	< 25	193	87.3%	80.0%
Serum albumin (g/dL)	≤ 4.0	172	85.6%	82.6%	0.536
	> 4.0	48	87.7%	76.2%
CEA (mg/dL)	≥ 5.0	102	86.7%	80.0%	0.715
	< 5.0	113	90.5%	82.0%
Decompression	+	183	88.4%	81.7%	0.514
	-	51	87.1%	74.8%
Location of tumor	Right side	69	82.6%	70.5%	0.103
	Left side	165	90.4%	84.3%
Tumor size (mm)	≥ 50	99	84.1%	76.9%	0.291
	< 50	121	90.4%	85%
Differentiation of tumor	tub1, tub2	222	89.9%	82.5%	0.001	6.282 (1.584-24.909)	0.009
	por, muc	12	50.0%	50.0%
Depth of tumor	T3	108	95.7%	92.3%	0.001	3.458 (1.324-9.031)	0.011
	T4	126	81.1%	69.2%
Intramural lymphatic invasion	+	157	90.8%	82.7%	0.449
	-	73	86.9%	79.4%
Intramural vascular invasion	+	164	94.2%	90.1%	0.152
	-	70	85.9%	76.7%
Lymph node involvement	+	120	92.5%	82.9%	0.332
	-	114	84.0%	77.7%
Lymph node dissection	D0, D1	31	60.7%	60.7%	0.014	0.958 (0.300-3.056)	0.942
	D2, D3	199	90.4%	83.0%
No. of lymph nodes harvested	< 12	73	83.3%	78.3%	0.314
	≥ 12	151	91.1%	81.0%
Postoperative complication	+	78	85.9%	75.6%	0.644
(≥ Grade 2)	-	156	89%	82.5%
Anastomotic leakage	+	18	100%	100%	0.069
	-	191	87.1%	78.7%
Curability	R0	219	91.3%	84.7%	< 0.001	6.162 (1.692-22.445)	0.006
	R1	15	39.7%	19.9%
Adjuvant chemotherapy	+	91	87.7%	81.8%	0.800
	-	143	88.8%	79.4%